Analysis of outcomes of the first line systemic therapy in patients with solitary, single and multiple metastases of renal cell carcinoma

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


BACKGROUND: Currently there are practically no works in the literature to assess the outcomes of systemic therapy in patients with solitary, single and multiple metastases of renal cell carcinoma.

AIM: The aim of the study was to analyze the outcomes of systemic drug therapy of the first line in patients with solitary, single and multiple metastases of renal cell carcinoma.

MATERIALS AND METHODS: The data of 981 patients with metastatic renal cell carcinoma who underwent systemic therapy of the first line at the City Oncological Hospital No. 62 in Moscow and the City Oncological Dispensary in St. Petersburg from 2006 to 2022 were retrospectively analyzed. All patients underwent clinical, laboratory and pathomorphological examination. 90 (9.2%) patients had solitary metastases, 252 (25.7%) single metastases and 639 (65.1%) multiple metastases. An analysis was made of the outcomes of 1st line therapy, which were conditionally divided into favorable, including all cases of complete response, partial response and stabilization, and unfavorable — progression during treatment, death or deregistration. Subsequently patients who had previously received chemotherapy or cytokine treatment were excluded from the analysis.

RESULTS: Complete response (3.3%) and deregistration (5.56%) were more often observed in patients with solitary metastases, stabilization more often occurred in patients with single metastases (51.1%), partial response (9.4%) and death (6.2%) — in patients with multiple metastases. In patients with multiple metastases treated with immune checkpoint inhibitors a partial response was observed in almost half of the cases. Stabilization and progression were observed in almost the same percentage of cases (about a quarter of cases), and only two patients had a fatal outcome, which is slightly lower than in patients receiving tyrosine kinase inhibitors. Frequent outcomes when using tyrosine kinase inhibitors were stabilization of the process (40.72% of cases) or progression (38.72%), a complete and partial response was rarely recorded. Significant differences in the occurrence of favorable and unfavorable outcomes were revealed in patients with multiple metastases, depending on the number of affected organs and the prescribed drug. When comparing the results of systemic therapy of the first line, a higher efficiency of tyrosine kinase inhibitors was observed in solitary metastases of tumors with a high and moderate degree of differentiation. Systemic therapy of G3 tumors with solitary metastases had low efficacy in the appointment of tyrosine kinase inhibitors in 27.27% of patients. Higher efficiency was noted in single and multiple metastases. The effectiveness of immune checkpoint inhibitors was revealed in 70.6% of patients with single and multiple metastases.

CONCLUSIONS: When choosing systemic therapy for metastatic renal cell carcinoma in clinical practice, it is necessary to take into account such prognostic factors as histological variants, the degree of differentiation of the tumor and the number of affected organs.

Full Text

Restricted Access

About the authors

Dmitry V. Semenov

City Clinical Oncology Dispensary; Saint Petersburg State University

Author for correspondence.
ORCID iD: 0000-0002-4335-8446

Cand. Sci. (Med.), oncourologist; assistant professor of the Department of Oncology

Russian Federation, Saint Petersburg; Saint Petersburg

Rashida V. Orlova

City Clinical Oncology Dispensary; Saint Petersburg State University

ORCID iD: 0000-0002-9368-5517
SPIN-code: 9932-6170

Dr. Sci. (Med.), Professor, chief specialist; head of the Department of Oncology

Russian Federation, Saint Petersburg; Saint Petersburg

Valery I. Shirokorad

Moscow City Oncological Hospital No. 62

ORCID iD: 0000-0003-4109-6451

Dr. Sci. (Med.), head of the Oncourological Unit

Russian Federation, Moscow

Stanislav V. Kostritsky

Moscow City Oncological Hospital No. 62

ORCID iD: 0000-0003-4494-1489
SPIN-code: 1421-2469


Russian Federation, Moscow

Yulia S. Korneva

Smolensk State Medical University; North-Western State Medical University named after I.I. Mechnikov; City Hospital No. 26

ORCID iD: 0000-0002-8080-904X
SPIN-code: 5169-7740
Scopus Author ID: 56657493900

Cand. Sci. (Med.), assistant professor of the Department of Pathological Anatomy, pathologist

Russian Federation, Smolensk; Saint Petersburg; Saint Petersburg


  1. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019;75(1):74–84. doi: 10.1016/j.eururo.2018.08.036
  2. Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11(3):79–87. doi: 10.14740/wjon1279
  3. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.2149
  4. Massari F, Rizzo A, Mollica V, et al. Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. Eur J Cancer. 2021;154:120–127. doi: 10.1016/j.ejca.2021.06.01
  5. Tsimafeyeu I, Shatkovskaya O, Krasny S, et al. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry. Cancer Rep (Hoboken). 2021;4(3): e1331. doi: 10.1002/cnr2.1331
  6. Abdou E, Pedapenki RM, Abouagour M, et al. Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2020;20(10): 831–840. doi: 10.1080/14737140.2020.1810572
  7. Tran J, Ornstein MC. Clinical Review on the Management of Metastatic Renal Cell Carcinoma. JCO Oncol Pract. 2022;18(3):187–196. doi: 10.1200/OP.21.00419
  8. Pecoraro A, Palumbo C, Knipper S, et al. Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. Clin Genitourin Cancer. 2020;18(5): e610–e618. doi: 10.1016/j.clgc.2020.02.001
  9. Shi H, Cao C, Wen L, et al C. Prognostic value of the ratio of maximum to minimum diameter of primary tumor in metastatic clear cell renal cell carcinoma. BMC Urol. 2022;22(1):95. doi: 10.1186/s12894-022-01047-y
  10. Buonerba C, Dolce P, Iaccarino S, et al. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2020;12(2):408. doi: 10.3390/cancers12020408
  11. Graham J, Wells JC, Dudani S, et al. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. Eur J Cancer. 2022;171: 124–132. doi: 10.1016/j.ejca.2022.05.00
  12. Zhou L, Liu Y, Mo J, et al. Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma. Urol Oncol. 2022;40(8):385.e1–385.e8. doi: 10.1016/j.urolonc.2022.05.01
  13. Gong J, Maia MC, Dizman N, et al. Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian J Urol. 2016;3(4):286–292. doi: 10.1016/j.ajur.2016.08.00
  14. Flippot R, Dalban C, Laguerre B, et al. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU26 NIVOREN Multicenter Phase II Study. J Clin Oncol. 2019;37(23):2008–2016. doi: 10.1200/JCO.18.02218
  15. Motzer RJ, Sharma P, McDermott DF, et al. CheckMate 025 phase III trial: outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). J Clin Oncol. 2016;34(2S):498. doi: 10.1200/jco.2016.34.2_suppl.498

Supplementary files

There are no supplementary files to display.

Copyright (c) 2023 Eco-Vector

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ №ФС77-65570 от 04 мая 2016 г.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies